Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis - Trial NCT06397911
Access comprehensive clinical trial information for NCT06397911 through Pure Global AI's free database. This Phase 2 trial is sponsored by Oneness Biotech Co., Ltd. and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Oneness Biotech Co., Ltd.
Timeline & Enrollment
Phase 2
Jul 16, 2024
Dec 31, 2026
Primary Outcome
The percentage change from baseline in Eczema Area and Severity Index (EASI) score
Summary
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy,
 pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with
 moderate-to-severe atopic dermatitis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06397911
Non-Device Trial